Bank Norwegian AS
Reference is made to previous announcements regarding MREL and the decision from the Board of Directors to apply to the Norwegian Financial Supervisory Authority (FSA) to merge Norwegian Finans Holding ASA and Bank Norwegian AS. The Norwegian FSA has on 5 January 2021 approved an application on the new company structure, leaving Bank Norwegian AS the ultimate parent company of the group after a merger. We are pleased to have received this approval, as a merger is expected to give positive synergies on administrative costs as well as reduce funding cost on future MREL eligible capital being issued from an operating company instead of a holding company.
Based on the approval, Norwegian Finans Holding ASA and Bank Norwegian AS will move forward with the formal merger process, including preparing the necessary documentation, applications and decisions by the companies’ governing bodies.
The ambition is to complete the merger process during first half of 2021, with accounting and fiscal effect from 1 January 2021, conditional on obtaining necessary approvals from relevant authorities.
Contact persons:
CFO Klara Lise Aasen; phone +47 47635583; kaa@banknorwegian.no
Head of Treasury Mats Benserud; phone +47 95891539; mbe@banknorwegian.no
This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About Globenewswire
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Rovsing A/S18.9.2025 11:58:00 CEST | Press release
Completion of share issue
Ålandsbanken18.9.2025 11:30:00 CEST | Press release
Ålandsbanken Abp announces a consent solicitation for its up to SEK 150,000,000 Tier 2 Notes due December 2041 and up to SEK 200,000,000 Tier 2 Notes due March 2043 and initiates procedures in writing
Novo Nordisk A/S18.9.2025 10:45:34 CEST | Press release
Novo Nordisk A/S: Ozempic® reduces the risk of heart attack, stroke and death by 23% compared to dulaglutide in the first head-to-head real-world study
Glice AG18.9.2025 10:41:41 CEST | Press release
Europe's Leading Research Institute Confirms Breakthrough: Swiss Company Glice Develops Synthetic Ice with Real-Ice Glide
Sparinvest SICAV18.9.2025 10:40:53 CEST | Pressemeddelelse
Sparinvest SICAV suspenderer handel med afdeling
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom